As of Friday close, Novo Nordisk A/S’s (NYSE:NVO) stock was up $0.01, moving up 0.01 percent to $91.30. The average number of shares traded per day over the past five days has been 4,906,900 shares. 2 times new highs have been achieved over the past 5 days, with a -$3.91 fall in that time frame. In the last twenty days, the average volume was 4,399,795, while in the previous 50 days, it was 3,883,530.
Since last month, NVO stock retreated -3.91%. Shares of the company fell to $90.50 on 09/21/23, the lowest level in the past month. A 52-week high of $100.88 was reached on 09/11/23 after having rallying from a 52-week low of $47.51. Since the beginning of this year, NVO’s stock price has risen by 34.92% or $23.63, and marked a new high 31 times. However, the stock has declined by -9.50% since its 52-week high.
Valuation Metrics
Right now, Novo Nordisk A/S (NVO) has a P/E ratio of about 21.57. The stock’s beta is 0.45. Besides these, the trailing price-to-sales (P/S) ratio of 11.26, the price-to-book (PB) ratio of 31.70.
The latest dividend of $0.2209 per share was paid out, which is -25.67% less than last year’s $0.2972. On Thursday August 10 2023, a $0.0763 dividend decrease was announced.
Financial Health
In the three months ended June 29, Novo Nordisk A/S’s quick ratio stood at 0.70, while its current ratio was 0.90, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.21, and the total debt-to-equity ratio was 0.28. On the profitability front, the trailing twelve-month gross margin is 84.40% percent. In the year ended June 29, EBITDA margin amounted to 45.79%, whereas operating margins totaled 42.80%. Based on annual data, NVO earned $21.03 billion in gross profit and brought in $25.06 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 56.10%. Return on equity (ROE) for the past 12 months was 81.40%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected Novo Nordisk A/S to report $0.63 quarterly earnings, the actual figure was $1.24 per share, beating the consensus estimate by 96.80%. During the quarter, the company generated $3.81 billion in EBITDA. The liabilities of Novo Nordisk A/S were 27.8 billion at the end of its most recent quarter ended June 29, and its total debt was $25.7 billion.
Technical Picture
This quick technical analysis looks at Novo Nordisk A/S’s (NVO) price momentum. With a historical volatility rate of 21.50%, the RSI 9-day stood at 36.56% on 22 September.
With respect to its five-day moving average, the current Novo Nordisk A/S price is down by -4.11% percent or -$3.91. At present, NVO shares trade -1.48% below its 20-day simple moving average and +9.07% percent above its 100-day simple moving average. However, the stock is currently trading approximately +16.39% above its SMA50 and +43.69% above its SMA200.
Stochastic coefficient K was 15.30% and Stochastic coefficient D was 18.11%, while ATR was 2.31. Given the Stochastic reading of 7.73% for the 14-day period, the RSI (14) reading has been calculated as 44.57%. As of today, the MACD Oscillator reading stands at -2.06, while the 14-day reading stands at -3.01.
Analyst Ratings
HSBC Securities launched its rating on Novo Nordisk A/S (NYSE: NVO) to a Buy in a note to investors on July 14, 2023. Novo Nordisk A/S (NVO) has been rated Overweight by analysts. According to 4 brokerage firms, NVO is a sell, and 6 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Novo Nordisk A/S stock as buy, with 15 recommending it as overweight.
With a median target price of $202.40, the current consensus forecast for the stock is $102.96 – $235.00. Based on these forecasts, analysts predict Novo Nordisk A/S (NVO) will achieve an average price target of $191.75.
